Accendra Health, Inc. (ACH)

NYSE: ACH · USD

$0.23

+0.03 (+12.9%)· Recorded snapshot

Market cap	17.6M
Revenue (ttm)	2.6B
Net income (ttm)	-302.1M
EPS (ttm)	-$3.95
Shares out	76.9M
Volume	1,112,988
Beta	1.57

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 2.6B
Net income (ttm): -302.1M
EPS (ttm): -$3.95
Market cap: 17.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC2.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ACH indicators

Market & fundamental data

Available fields

231

Groups with data

Currency

USD

Showing 231 of 231 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000075252
Company name	Accendra Health, Inc.
Country	United States
Country code	US
CUSIP number	690732102
Earnings date	2026-11-05
Earnings time	amc
Employees	6,500
Employees change	-16,700
Employees growth	-71.98%
Enterprise value	$1.8B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1882
In index	RUSSELL2000
Industry	Medical Distribution
Is primary listing	Yes
Is SPAC	No
ISIN number	US6907321029
Last earnings date	2026-08-10
Last refreshed	2026-10-28
Last stock split date	2010-04-01
Last stock split type	Forward
Market cap	$17.6M
Market cap category	Nano-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$0.23
Price currency	USD
Sector	Healthcare
Stock price date	2026-10-28
Symbol	ACH
U.S. state	Virginia
Website	https://www.accendrahealth.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	1x
Earnings yield	-1,720%
EV/EBIT	56.87x
EV/EBITDA	6.34x
EV/Sales	0.69x
FCF / EV yield	-19.53%
FCF yield	-2,147.28%
Forward EV/Sales	0.73x
Forward P/S	0.01x
Industry forward P/E	19.16x
Industry P/E	27.41x
P/S ratio	0.01x
Price/EBITDA ratio	0.06x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	1.21%
EBITDA margin	10.89%
Gross margin	44.83%
Operating margin	1.21%
Pretax margin	-4.36%
Profit margin	-11.41%
Profit per employee	$-46,483
Revenue per employee	$407,268
ROA	0.64%
ROA (5Y)	3.56%
ROCE	2.23%
ROE (5Y)	-36.01%
ROIC	2.42%
ROIC (5Y)	8.46%
SBC / revenue	0.4%
Tax / revenue	-0.18%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	3
EPS growth years	0
Gross profit growth	-9.3%
Gross profit growth (Q)	-18.85%
Gross profit growth 3Y	-15.07%
Gross profit growth 5Y	-5.63%
Net income growth quarters	3
Net income growth years	0
Operating income growth	-84.2%
Operating income growth 3Y	-28.11%
Operating income growth 5Y	-41.08%
Revenue growth	-3.3%
Revenue growth (Q)	-10.07%
Revenue growth (QoQ)	-2.32%
Revenue growth 10Y	-12.36%
Revenue growth 3Y	-36.08%
Revenue growth 5Y	-22.33%
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-176.8M
Depreciation and amortization	$256.1M
EBIT	$32.2M
EBITDA	$288.2M
EPS	$-3.95
FCF per share	$-4.64
Financing cash flow	$-157.3M
Free cash flow	$-357.2M
Free cash flow minus SBC	$-367.9M
Gross profit	$1.2B
Income taxes	$-4.9M
Investing cash flow	$268.2M
Net borrowing	$-135M
Net cash flow	$-69.4M
Net income	$-302.1M
Operating cash flow minus SBC	$-191.1M
Operating income	$32.2M
Revenue	$2.6B
Stock-based compensation	$10.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.37
Book value per share	$-7.16
Debt / EBITDA	4.89
Goodwill	$1.2B
Interest coverage	0.29
Long-term assets	$1.8B
Long-term liabilities	$2B
Net cash (debt)	$-1.8B
Net cash / market cap	-10,893.3%
Net debt / EBITDA	6.29
Piotroski F-Score	3
Property, plant and equipment	$305.7M
Shareholders' equity	$-550.9M
Tangible book value	$-1.9B
Tangible book value per share	$-24.15
Total assets	$2.1B
Total cash	$7.7M
Total debt	$1.8B
Total liabilities	$2.7B
WACC	4.93%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.85
Current assets	$271.4M
Current liabilities	$666.2M
Current ratio	0.41
Inventory turnover	20.49
Net working capital	$-364M
Quick ratio	0.19
Working capital	$-394.8M
Working capital turnover	-6.87

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.47%
Dividend growth (10Y)	-35.48%
Dividend growth (3Y)	-77.3%
Dividend growth (5Y)	-60.35%
Dividend per share	$0.00
Dividend yield	0%
Last dividend	$0.00
Shareholder yield	0.47%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-99.31%
10Y return CAGR	-38.57%
10Y total return	-99.23%
150-day SMA	$2.24
15Y price change	-99.27%
15Y return CAGR	-26.73%
15Y total return	-99.06%
1D price change	12.95%
1M price change	-68.56%
1M total return	-68.56%
1W price change	-12.84%
1W total return	-12.84%
1Y price change	-95.94%
1Y return CAGR	-95.95%
1Y total return	-95.94%
20-day SMA	$0.33
200-day SMA	$2.26
20Y price change	-98.97%
20Y return CAGR	-19.01%
20Y total return	-98.52%
3M price change	-93.09%
3M total return	-93.09%
3Y price change	-98.4%
3Y return CAGR	-74.77%
3Y total return	-98.4%
50-day SMA	$0.75
50-day SMA vs 200-day SMA	50under200
52-week high	$5.52
52-week high date	2025-10-28
52-week low	$0.19
52-week low date	2026-10-23
5Y price change	-99.36%
5Y return CAGR	-63.63%
5Y total return	-99.36%
6M price change	-93.49%
6M total return	-93.49%
All-time high	$49.16
All-time high date	2021-06-09
All-time low	$0.19
All-time low date	2026-10-23
Average true range (ATR)	$0.06
Average volume	2.2M
Beta (1Y)	2.45
Beta (2Y)	1.4
Beta (5Y)	1.57
Change from 52-week high	-95.84%
Change from 52-week low	20.11%
Change from all-time high	-99.55%
Change from all-time low	16.54%
Change from open	6.65%
Day's gap	5.91%
Dollar volume	$255,319
High price	$0.23
Low price	$0.21
Monthly RSI	30.39
Open price	$0.22
Position in 52-week range	93.27%
Premarket change	3.35%
Premarket close	$0.20
Premarket price	$0.21
Premarket volume	7.1K
Previous close	$0.20
Price vs 150-day SMA	-90.07%
Price vs 20-day SMA	-32.44%
Price vs 200-day SMA	-90.15%
Price vs 50-day SMA	-70.42%
Relative volume	0.51
RSI	19.89
Sharpe ratio	-2.44
Sharpe ratio (3Y)	-1.17
Sharpe ratio (5Y)	-0.92
Sortino ratio	-2.79
Sortino ratio (3Y)	-1.43
Sortino ratio (5Y)	-1.14
Volume	1.1M
Weekly RSI	24.77
YTD price change	-92.05%
YTD total return	-92.05%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	56.2M
Float percentage	73.03%
Shares change (QoQ)	0.34%
Shares change (YoY)	-0.47%
Shares held by insiders	9.79%
Shares held by institutions	79.52%
Shares outstanding	76.9M
Short % of float	15%
Short % of shares	10.95%
Short ratio	6.5 days

Deeper analysis on ACH

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ACH report

Is a complete ACH research report available?

No complete published report is available for Accendra Health, Inc. (ACH) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Accendra Health, Inc. (ACH)

Price

Financial snapshot

Fair-value bridge

Latest news · ACH

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ACH indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ACH

Frequently asked questions